Register Login

PALVELLA THERAPEUTICS, INC. (PVLA)

(90% Positive) PALVELLA THERAPEUTICS, INC. (PVLA) Announces Enrollment Update for framework Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 7, 2026, 11:31 a.m.

    📋 PALVELLA THERAPEUTICS, INC. (PVLA) - Clinical Trial Update

    Filing Date: 2026-04-07

    Accepted: 2026-04-07 07:30:15

    Event Type: Clinical Trial Update

    Event Details:

    PALVELLA THERAPEUTICS, INC. (PVLA) Announces Clinical Trial Update PALVELLA THERAPEUTICS, INC. (PVLA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: framework, contained
    • Diseases/Conditions: some cases
    • Clinical Stage: clinical trial
    • Collaboration: Company
      • Targeting announcement in 2026
      • anticipated by year end 2026
      • Targeting the Causal Mevalonate Pathway Target: Mevalonate Pathway Tissue: Epidermis & Dermis Site of pathogenesis-directed therapy An on-target, in-tissue approach could result in significant clinical improvement *HMGCR = 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Image sources: Milani D, Warbasse E, Chen WS. Porokeratosis. PathologyOutlines.com website. * Using QTORIN™, we considered and tested a wide range of mevalonate pathway inhibitors QTORIN™ Pitavastatin: On Target, In Tissue QTORIN™ PITAVASTATIN Molecule Potency Optimal Skin PK Stability Pitavastatin Mev. Inhibitor 2 Mev. Inhibitor 3 Mev. Inhibitor 4 Mev. Inhibitor 5 Mev. Inhibitor 6 Mev. Inhibitor 7 Did not meet some or all pre-defined target product attributes Pitavastatin is an FDA-approved next-generation oral statin for patients with primary hyperlipidemia and mixed dyslipidemia Superior inhibition of the mevalonate pathway compared to all molecules evaluated Key characteristics: Payload: > 2% concentration achieved Dermal penetration: in vitro penetration test confirms > IC90 Low systemic absorption Encouraging preliminary drug stability IP: Filed formulation & method of use IP and licensed Yale IP Platform QTORIN™ QTORIN™: New Product Development Engine VALIDATION OF QTORIN™ PLATFORM Two positive clinical study readouts (Phase 3 SELVA trial and Phase 2 TOIVA trial results) PLANNING TO PURSUE PLATFORM DESIGNATION We expect to apply for FDA’s Platform Technology Designation Program following QTORIN™ rapamycin’s targeted approval in 2027

    🔬 Clinical Development Pipeline (PALVELLA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    QTORIN 3.9% Rapamycin Anhydrous Gel DRUG Phase PHASE3 Microcystic Lymphatic Malformation ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: PALVELLA THERAPEUTICS, INC.
    • Ticker Symbol: PVLA

Search

News categories